Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight (NASDAQ:RXST), an ophthalmic medical device company, reported mixed Q2 2025 financial results. Revenue decreased 4% year-over-year to $33.6 million, despite a 13% increase in Light Adjustable Lens (LAL) procedure volume to 27,380 units. The company's Light Delivery Device (LDD) installed base grew 34% to 1,084 units, though LDD sales declined 49% year-over-year.
The company reported a net loss of $(0.29) per share, compared to $(0.16) in Q2 2024. Gross margin improved to 74.9% from 69.5%. Notable developments include FDA approval for expanded LAL dioptric power range, launches in South Korea and Singapore, and a commercial organization realignment. RxSight maintained its full-year 2025 guidance of $120-130 million in revenue.
RxSight (Nasdaq: RXST), a medical device company specializing in customized vision solutions for cataract surgery patients, has appointed Raymond W. Cohen to its Board of Directors. Cohen, a seasoned medical technology executive with over 40 years of experience, notably led Axonics Inc. to generate over $1 billion in revenue within four years before its $3.7 billion acquisition by Boston Scientific in 2024.
As chairman of SoniVie Ltd., Cohen recently orchestrated its $600 million sale to Boston Scientific in March 2025. He currently serves on multiple healthcare company boards and brings extensive experience in scaling medical technology companies. Cohen expressed confidence in helping RxSight strengthen its position in the premium intraocular lens market and accelerate revenue and profit growth.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast through the company's investor relations website.
RxSight (NASDAQ: RXST), an ophthalmic medical device company, reported disappointing preliminary Q2 2025 results and significantly lowered its full-year guidance. Revenue is expected to be $33.6 million, down 4% year-over-year and 11% sequentially.
The company sold 27,380 Light Adjustable Lenses (up 13% YoY but down 1% QoQ) and 40 Light Delivery Devices (down 49% YoY and 45% QoQ). The installed base grew 34% YoY to 1,084 LDDs.
RxSight revised its 2025 guidance downward, now expecting revenue of $120-130 million (previously $160-175 million), while increasing gross margin guidance to 72-74% and reducing operating expense projections to $145-155 million.
RxSight, Inc. (NASDAQ: RXST), a company specializing in ophthalmic medical devices for post-cataract surgery vision customization, has announced its participation in the upcoming Stifel Virtual Ophthalmology Forum. The company's management team will engage in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties can access both the live and archived versions of the presentation through RxSight's investor relations website at investors.rxsight.com.
RxSight, a specialized ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Bank of America Healthcare Conference in Las Vegas.
The company's management team is set to deliver their presentation on Wednesday, May 14, 2025, at 3:40 PM Pacific Time (6:40 PM Eastern Time). Investors and interested parties can access both the live presentation and archived recording through the company's investor relations website at https://investors.rxsight.com/.
This presentation at a major healthcare conference represents an opportunity for RxSight to showcase their innovations in customized vision solutions for cataract surgery patients. The company's participation in this significant industry event demonstrates their commitment to engaging with the investment community and sharing their business developments.
RxSight Inc (NASDAQ: RXST), an ophthalmic medical device company focused on providing customized vision solutions for post-cataract surgery patients, has scheduled its Q1 2025 financial results announcement for May 7, 2025 after market close.
The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss the results. Investors can participate by dialing (800) 715-9871 or (646) 307-1963 with conference code 8740296. A live audio-only webcast will be available through the investor relations website, with a recording accessible afterward.
RxSight (NASDAQ: RXST) announced preliminary Q1 2025 revenue of $37.9 million, showing 28% year-over-year growth but a 6% decrease from Q4 2024. The company reported selling 27,579 Light Adjustable Lenses, a 36% increase from Q1 2024, and 73 Light Delivery Devices, expanding the installed base to 1,044 LDDs (43% growth year-over-year).
Due to headwinds in the premium IOL market and broader economy, RxSight revised its 2025 guidance downward. The new full-year revenue guidance is $160.0-175.0 million (down from $185.0-197.0 million), representing 14-25% growth. Operating expenses are now projected at $150.0-160.0 million, reduced from $165.0-170.0 million, including non-cash stock-based compensation of $27.0-30.0 million.
RxSight (NASDAQ: RXST), an ophthalmic medical device company focused on post-cataract surgery customized vision solutions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's management will engage in a fireside chat scheduled for April 8, 2025, at 9:45 AM PT / 12:45 PM ET. Interested parties can access both the live presentation and archived recording through RxSight's investor relations website at https://investors.rxsight.com/.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
